Ficerafusp alfa aims to enhance tumor targeting, says Bicara Therapeutics

Ficerafusp alfa aims to enhance tumor targeting, says Bicara Therapeutics
Bicara Therapeutics advances tumor therapy

Bicara Therapeutics has unveiled details of Ficerafusp alfa, a therapy designed to address inadequate tumor penetration in solid tumors, such as head and neck squamous cell carcinoma (HNSCC).

The approach employs two complementary mechanisms: targeting EGFR to focus activity on the tumor and trapping TGF-beta within the tumor microenvironment. This dual strategy aims to enable more effective Tumor Penetration.

Earlier this year, Bicara Therapeutics began the FORTIFI-FLEX trial targeting HPV-negative head and neck cancer with a specific dosing regimen. The company has also scheduled a financial results announcement and business update for November 9. These developments come as the company continues to advance its pipeline for solid tumor therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.